B
Bruce Neal
Researcher at The George Institute for Global Health
Publications - 620
Citations - 109123
Bruce Neal is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Population & Blood pressure. The author has an hindex of 108, co-authored 561 publications receiving 87213 citations. Previous affiliations of Bruce Neal include National Institutes of Health & University of the Western Cape.
Papers
More filters
Journal ArticleDOI
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
Megumi Oshima,Megumi Oshima,Brendon L. Neuen,Meg Jardine,Meg Jardine,George L. Bakris,Robert Edwards,Adeera Levin,Kenneth W. Mahaffey,Bruce Neal,Bruce Neal,Bruce Neal,Carol A. Pollock,Carol A. Pollock,Norman Rosenthal,Takashi Wada,David C. Wheeler,David C. Wheeler,Vlado Perkovic,Vlado Perkovic,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink +21 more
TL;DR: It is suggested that canagliflozin reduces the risk of anaemia-associated outcomes, including the need for erythropoiesis-stimulating agents, among patients with type 2 diabetes and chronic kidney disease.
Journal ArticleDOI
The World Health Organization--International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments.
Bruce Neal,Stephen MacMahon +1 more
TL;DR: In this article, the authors present a systematic overview of the major ongoing randomized controlled trials and meta-analyses of these studies, which will involve about 270,000 patients and 1.1 million patient-years of follow-up.
Journal ArticleDOI
ADVANCE Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline
Anushka Patel,Bruce Neal,John Chalmers,Stephen MacMahon,Simon Heller,C. Y. Pan,Mark Woodward,S. Coleman +7 more
TL;DR: The ADVANCE trial as discussed by the authors is a 2 × 2 factorial randomized controlled trial, where participants were randomized to perindopril/indapamide (initially 2.0/0.625 mg daily, increasing to 4.0 /1.25 mg daily after 3 months) or matching placebo; and to an intensive gliclazide MR-based glucose control regimen aiming for a haemoglobin A1c (HbA1c) value of 6.5% or lower, or local standard therapy.
Journal ArticleDOI
Efficacy and safety of routine blood pressure lowering in older patients with diabetes: Results from the advance trial
Toshiharu Ninomiya,Sophia Zoungas,Sophia Zoungas,Bruce Neal,Mark Woodward,Mark Woodward,Anushka Patel,Vlado Perkovic,Alan Cass,Mark E. Cooper,Diederick E. Grobbee,Pavel Hamet,Stephen B. Harrap,Lisheng Liu,Giuseppe Mancia,Carl Erik Mogensen,Neil R Poulter,Anthony Rodgers,Bryan Williams,Stephen MacMahon,John Chalmers +20 more
TL;DR: Routine administration of perindopril–indapamide lowers blood pressure safely and reduces the risk of major clinical outcomes in patients of at least 75 years with type 2 diabetes.
Journal ArticleDOI
The Effects of a Community-Based Sodium Reduction Program in Rural China - A Cluster-Randomized Trial.
Nicole Li,Lijing L. Yan,Lijing L. Yan,Wenyi Niu,Cong Yao,Xiangxian Feng,Jiguo Zhang,J. Shi,Y. Zhang,Ruo Zhang,Zhixin Hao,Hongling Chu,Hongling Chu,Xian Li,Jianji Pan,Zhifang Li,Jixin Sun,Baosen Zhou,Y. Zhao,Yan Yu,Michael M. Engelgau,Darwin R. Labarthe,Jixiang Ma,Stephen MacMahon,Paul Elliott,Y. F. Wu,Y. F. Wu,Bruce Neal +27 more
TL;DR: There were clear differences in population sodium and potassium intake between villages that were most likely a consequence of increased use of salt substitute.